New insights and therapeutics for immune-mediated thrombocytopenia

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 1, 2008, Pages 71-84

  Metjian, Ara ^a   Abrams, Charles S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AMG531; Eltrombopag; Immune mediated thrombocytopenia; Thrombocytopenia; Thrombopoeitin mimetics; Thrombopoietin

Indexed keywords

AKR 501; AMGEN MEGAKARYOPOIESIS PROTEIN 531; AUTOANTIBODY; CARBOPLATIN; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; CORTICOTROPIN; CORTISONE; DANAZOL; DAPSONE; DEXAMETHASONE; ELTROMBOPAG; ERYTHROPOIETIN; ETANERCEPT; GENE PRODUCT; GW 395058; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PACLITAXEL; PLACEBO; POLYETHYLENE GLYCOL RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH DEVELOPMENT FACTOR; PREDNISONE; RECOMBINANT THROMBOPOIETIN; RITUXIMAB; SB 559448; STEROID; THROMBOPOIETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN MPL;

ABSENCE OF SIDE EFFECTS; ACUTE LEUKEMIA; APLASTIC ANEMIA; BINDING AFFINITY; BLEEDING; CAPILLARY RESISTANCE; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GYNECOLOGIC CANCER; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; IMMUNOMODULATION; INFECTION; LUNG CANCER; MEGAKARYOCYTE; MOLECULAR CLONING; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYLEPROLIFERATIVE LEUKEMIA VIRUS; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; RECEPTOR BINDING; REFRACTORY THROMBOCYTOPENIA; REVIEW; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SPLENECTOMY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE RELEASE REACTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS;

ANTIBODIES, MONOCLONAL; BENZOIC ACIDS; CARRIER PROTEINS; CD40 LIGAND; DEXAMETHASONE; HUMANS; HYDRAZINES; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR MIMICRY; POLYETHYLENE GLYCOLS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT PROTEINS; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 38049153586     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.1.71     Document Type: Review

References (146)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N. Engl. J. Med 346(13), 995-1008 (2002).
2. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88(1), 3-40 (1996).
3. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br. J. Haematol. 120(4), 574-596 (2003).
4. Whipple A. Splenectomy as a therapeutic measure in thrombocytopenic purpura haemorrhagica. Surg. Gynecol. Obstet. 42, 329-341 (1926).
5. Meyers MM, Bethell FH. Administration of ACTH in hypersplenic syndromes. J. Lab. Clin. Med. 36(6), 965-966 (1950).
6. Bethell FM, Meyers MC, Miller S, Bullock WH. Effects of ACTH and cortisone on idiopathic thrombocytopenic purpura. Trans. Assoc. Am. Physicians 64, 199-203 (1951).
7. Verlin M, Laros RK Jr, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am. J. Hematol. 1(1), 97-104 (1976).
8. Sussman LN. Azathioprine in refractory idiopathic thrombocytopenic purpura. JAMA 202(4), 259-263 (1967).
9. Proctor SJ, Jackson G, Carey P, Stark A. Short-course α-interferon therapy in severe unresponsive immune thrombocytopenic purpura. Lancet 1(8591), 947 (1988).
10. Kelsey PR, Schofield KP, Geary CG. Refractory idiopathic thrombocytopenic purpura. (ITP) treated with cyclosporine. Br. J. Haematol. 60(1), 197-198 (1985).
11. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br. J. Haematol. 117(3), 712-715 (2002).
12. Godeau B, Oksenhendler E, Bierling P. Dapsone for autoimmune thrombocytopenic purpura. Am. J. Hematol. 44(1), 70-72 (1993).
13. McMinn JR Jr, Cohen S, Moore J et al. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am. J. Hematol. 73(2), 135-140 (2003).
14. Ahn YS, Harrington WJ, Simon SR et al. Danazol for the treatment of idiopathic thrombocytopenic purpura. N. Eng. J. Med. 308(23), 1396-1399 (1983).
15. George JN. Management of patients with refractory immune thrombocytopenic purpura. J. Thromb. Haemost. 4(8), 1664-1672 (2006).
16. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97(9), 2549-2554 (2001).
17. George JN, Vesely SK. Immune thrombocytopenic purpura - let the treatment fit the patient. N. Engl. J. Med. 349(9), 903-905 (2003).
18. Dameshek W, Miller EB. The megakaryocytes in idiopathic thrombocytopenic purpura, a from of hypersplenism. Blood 1(1), 27-51 (1946).
19. Stoll D, Cines DB, Aster RH, Murphy S. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood 65 (3), 584-588 (1985).
20. 111Indium-oxine-labeled platelets in idiopathic thrombocytopenic purpura: a quantitative study. Am. J. Hematol. 12(2), 167-177 (1982).
21. 51Cr-labeled platelets differ. Blood 67(1), 86-92 (1986).
22. Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N. Engl. J. Med. 320(15), 974-980 (1989).
23. Ballem PJ, Segal GM, Stratton JR et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J. Clin. Invest. 80(1), 33-40 (1987).
24. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 103(4), 1364-1369 (2004).
25. Keleman EC, I.; Tanos, B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta. Haematol. 20(6), 350-355 (1958).
26. De Gabriele G, Penington DG. Physiology of the regulation of platelet production. Br. J. Haematol. 13(2), 202-209 (1967).
27. Wendling F, Varlet P, Charon M, Tambourin P. MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology 149(2), 242-246 (1986).
28. Le Coniat M, Souyri M, Vigon I et al. The human homolog of the myeloproliferative virus maps to chromosome band 1p34. Hum. Genet. 83(2), 194-196 (1989).
29. Souyri M, Vigon I, Penciolelli JF et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 63(6), 1137-1147 (1990).
30. Vigon I, Mornon JP, Cocault L et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc. Natl. Acad. Sci. USA 89(12), 5640-5644 (1992).
31. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 82(5), 1395-1401 (1993).
32. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl- deficient mice. Science 265(5177), 1445-1447 (1994).
33. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 87(6), 2162-2170 (1996).
34. Kimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc. Natl. Acad. Sci. USA 95(3), 1195-1200 (1998).
35. Drachman JG, Griffin JD, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J. Biol. Chem. 270(10), 4979-4982 (1995).
36. Miyakawa Y, Drachman JG, Gallis B, Kaushansky A, Kaushansky K. A structure-function analysis of serine/threonine phosphorylation of the thrombopoietin receptor, c-Mpl. J. Biol. Chem. 275(41), 32214-32219 (2000).
37. Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc. Natl. Acad. Sci. USA 92(12), 5292-5296 (1995).
38. Yamada M, Komatsu N, Okada K et al. Thrombopoietin induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in a human thrombopoietin-dependent cell line. Biochem. Biophys. Res. Commun. 217(1), 230-237 (1995).
39. Rojnuckarin P, Miyakawa Y, Fox NE et al. The roles of phosphatidylinositol 3-kinase and protein kinase Cζ for thrombopoietin-induced mitogen-activated protein kinase activation in primary murine megakaryocytes. J. Biol. Chem. 276(44), 41014-41022 (2001).
40. Kaushansky K. Thrombopoietin: a tool for understanding thrombopoiesis. J. Thromb. Haemost. 1(7), 1587-1592 (2003).
41. de Sauvage FJ, Hass PE, Spencer SD et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369(6481), 533-538 (1994).
42. Lok S, Kaushansky K, Holly RD et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369(6481), 565-568 (1994).
43. Kaushansky K, Lok S, Holly RD et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369(6481), 568-571 (1994).
44. Bartley TD, Bogenberger J, Hunt P et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77(7), 1117-1124 (1994).
45. Wendling F, Maraskovsky E, Debili N et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 369(6481), 571-574 (1994).
46. Sohma Y, Akahori H, Seki N et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett. 353(1), 57-61 (1994).
47. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J. Clin. Invest. 115(12), 3339-3347 (2005).
48. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance routine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85(7), 1719-1726 (1995).
49. van Willigen G, Gorter G, Akkerman JW. Thrombopoietin incrcases platelet sensitivity to α-thrombin via activation of the ERK2-cPLA2 pathway. Thromb. Haemost. 83(4), 610-616 (2000).
50. Akkerman JW. Thrombopoietin and platelet function. Semin. Thromb. Hemost. 32(3), 295-304 (2006).
51. Hunt P, Li YS, Nichol JL et al. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood 86(2), 540-547 (1995).
52. Hirayama Y, Sakamaki S, Matsunaga T et al. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. Blood 92(1), 46-52 (1998).
53. Kosugi S, Kurata Y, Tomiyama Y et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br. J. Haematol. 93(3), 704-706 (1996).
54. Tahara T, Usuki K, Sato H et al. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br. J. Haematol. 93(4), 783-788 (1996).
55. Emmons RV, Reid DM, Cohen RL et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87(10), 4068-4071 (1996).
56. Corazza F, Hermans C, D'Hondt S et al. Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia. Blood 107(6), 2525-2530 (2006).
57. De Gabriele G, Penington DG. Regulation of platelet production: 'thrombopoietin'. Br J. Haematol. 13(2), 210-215 (1967).
58. Nagasawa T, Hasegawa Y, Shimizu S et al. Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects. Br. J. Haematol. 101(2), 242-244 (1998).
59. Dahlen DD, Broudy VC, Drachman J. Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs. Blood 103(1), 102-108 (2003).
60. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 8500), 2720-2730 (1995).
61. Fielder PJ, Gurney AL, Stefanich E et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 87(6), 2154-2161 (1996).
62. Terashi K, Oka M, Ohdo S et al. Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Antimicrob. Agents Chemother. 43(1), 21-24 (1999).
63. Harker LA. Therapeutic cytokine stimulation of thrombocytopoiesis. Transfus. Sci. 19(2), 149-162 (1998).
64. Basset RL, Rasko JE, Clarke K et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348(9037), 1279-1281 (1996).
65. Hokom MM, Lacey D, Kinstler OB et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 86(12), 4486-4492 (1995).
66. Fanucchi M, Glaspy J, Crawford J et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N. Engl. J. Med. 336(6), 404-409 (1997).
67. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100(10), 3457-3469 (2002).
68. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann. Intern. Med. 132(5), 364-368 (2000).
69. Vadhan-Raj S, Murray LJ, Bueso-Ramos C et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann. Intern. Med. 126(9), 673-681 (1997).
70. Harker LA, Marzec UM, Novembre F et al. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor. Blood 91(12), 4427-4433 (1998).
71. Harker LA, Carter RA, Marzec UM et al. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy. Blood 92, (1998) (Abstract 707a).
72. Kuter DJ, Goodnough LT, Romo J et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 98(5), 1339-1345 (2001).
73. Goodnough LT, Kuter DJ, McCullough J et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 98(5), 1346-1351 (2001).
74. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 100(2), 728-730 (2002).
75. Rice L, Nichol JL, McMillan R, Roskos LK, Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am. J. Hematol. 68(3), 210-214 (2001).
76. Hua B, Zou N, Wang S, Zhu T, Zhao Y. Multiple cycles of recombinant human thrombopoietin therapy in a patient with chronic refractory idiopathic thrombocytopenic purpura. Blood Coagul. Fibrinolyis 16(4), 291-295 (2005).
77. Fontenay-Roupie M, Dupont JM, Picard F et al. Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia. Leuk. Res. 22(6), 527-535 (1998).
78. Ferrajoli A, Talpaz M, Kurzrock R et al. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. Leuk. Lymphoma 30(3-4), 279-292 (1998).
79. Kizaki M, Miyakawa Y, Ikeda Y. Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome. Br. J. Haematol. 122(5), 764-767 (2003).
80. Matsuda A, Misumi M, Ishikawa M et al. Long-term improvement of anaemia in a patient with aplastic anaemia by short-term administration of pegylated recombinant human megakaryocyte growth and development factor. Br. J. Haematol. 125(6), 818-819 (2004).
81. Archimbaud E, Ottmann OG, Yin JA et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 94(11), 3694-3701 (1999).
82. Schiffer CA, Miller K, Larson RA et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 95(8), 2530-2535 (2000).
83. Bolwell B, Vredenburgh J, Overmoyer B et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant. 26(2), 141-145 (2000).
84. Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98(12), 3241-3248 (2001).
85. Basser RL, O'Flaherty E, Green M et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99(7), 2599-2602 (2002).
86. Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J. Thromb. Haemost. 2, 1082-1095 (2004).
87. Key NS. Inhibitors in congenital coagulation disorders. Br. J. Haematol. 127(4), 379-391 (2004).
88. Cwirla SE, Balasubramanian P, Duffin DJ et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276(5319), 1696-1699 (1997).
89. de Setres M, Ellis B, Dillberger JE et al. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man. Stem Cells 17(4), 203-209 (1999).
90. Deng B, Banu N, Malloy B et al. An agonist murine monoclonal antibody to the human c-Mpl receptor stimulates megakaryocytopoiesis. Blood 92(6), 1981-1988 (1998).
91. Rice L. Drug evaluation: AMG-531 for the treatment of thrombocytopenias. Curr. Opin. Investig. Drugs 7(9), 834-841 (2006).
92. Nichol JL. AMG 531: an investigational thrombopoiesis-stimulating peptibody. Pediatr. Blood Cancer 47(5 Suppl.), 723-725 (2006).
93. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin. Pharmacol. Ther. 76(6), 628-638 (2004).
94. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 25(2), 52-60 (2004).
95. Newland A, Caulier MT, Kappers-Klunne M et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br. J. Haematol. 135(4), 547-553 (2006).
96. Bussel JB, Kuter DJ, George JN et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N. Engl. J. Med. 355(16), 1672-1681 (2006).
97. Kuter D, Bussel JB, George J et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Presented at: 48th Annual Meeting of the American Society of Hematology, Orlando, FL, USA, 9-12 December 2006 (Abstract 476).
98. Yan XQ, Lacey D, Fletcher F et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 86(11), 4025-4033 (1995).
99. Ulich TR, del Castillo J, Senaldi G et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 87(12), 5006-5015 (1996).
100. Yanagida M, Ide Y, Imai A et al. The role of transforming growth factor-β in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br. J. Haematol. 99(4), 739-745 (1997).
101. Kumagai Y, Fujita T, Ozaki M et al. Platelet aggregation analysis of AMG 531 in a randomized, placebo-controlled study in healthy Japanese subjects. Presented at: 48th Annual Meeting of the American Society of Hematology, Orlando, FL, USA, 9-12 December 2006
102. Duffy KJ, Darcy MG, Delorme E et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J. Med. Chem. 44(22), 3730-3745 (2001).
103. Luengo JI, Duffy KJ, Shaw AN et al. Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. Blood 104(11), 2910 (2004).
104. Erickson-Miller C, Delorme E, Giampa L et al. Biological activity and selectivity for Tpo Receptor of the orally bioavailable, small molecule Tpo receptor agonist, SB-497115. Blood 104(11), 2912 (2004).
105. Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight tpor agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood 104(11), 3888 (2004).
106. Jenkins J, Nicholl R, Williams D et al. An oral, non-petide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects. Blood 104(11), 797a (2004) (Abstract 2916).
107. Jenkins JM, Williams D, Deng Y et al. Phase I clinical study of eltrombopag, an oral, non-peptide thrombopoietin receptor agonist. Blood 109(11), 4739-4741 (2007).
108. Bussel JB, Cheng G, Saleh M et al. Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): a randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor. Presented at: 48th Annual Meeting of the American Society of Hematology, Orlando, FL, USA, 9-12 December 2006.
109. McHutchison JA, Dusheiko G, Shiffman L et al. Eltrombopag, an oral platelet growth factor, facilitates initiation of interferon therapy in subjects with HCV associated thrombocytopenia: results from a Phase II placebo controlled, double-blind, dose-ranging study. Hepatology 44(S1), 692A, (2006) (Abstract LB693).
110. Su S-F, Peng B, Williams D et al. A Phase I study to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of an oral platelet growth factor (SB-559448) in healthy subjects. Presented at: 48th Annual Meeting of the American Society of Hematology, Orlando, FL, USA, 9-12 December 2006.
111. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Presented at: 48th Annual Meeting of the American Society of Hematology, Orlando, FL, USA, 9-12 December 2006.
112. Erickson-Miller CL, DeLorme E, Tian SS et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp. Hematol. 33(1), 85-93 (2005).
113. Orita T, Tsunoda H, Yabuta N et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 105(2), 562-566 (2005).
114. Frederickson S, Renshaw MW, Lin B et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc. Natl Acad. Sci. USA 103(39), 14307-14312 (2006).
115. Nakamura T, Miyakawa Y, Miyamura A et al. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood 107(11), 4300-4307 (2006).
116. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63(8), 803-843 (2003).
117. Eisenberg R. SLE - Rituximab in lupus. Arthritis Res. Ther. 5(4), 157-159 (2003).
118. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2(1), 20-27 (2006).
119. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy ef B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004).
120. Patino W, Sarode R. Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura. J. Clin. Apher. 22(1), 17-20 (2007).
121. Cooper N, Stasi R, Cunningham-Rundles S et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol. 125(2), 232-239 (2004).
122. Godeau B, Fain O, Porcher R et al. Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective Phase II study. Presented at: 48th Annual Meeting of the American Society of Hematology, Orlando, FL, USA, 9-12 December 2006.
123. Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med. 146(1), 25-33 (2007).
124. Dubbeld P, van der Heul C, Hillen HF. Effect of high-dose dexamethasone in prednisone-resistant autoimmune thrombocytopenic purpura (ITP). Neth. J. Med. 39(1-2), 6-10 (1991).
125. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N. Engl. J. Med. 330(22), 1560-1564 (1994).
126. Wali YA, Al Lamki Z, Shah W, Zacharia M, Hassan A. Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. Pediatr. Hematol. Oncol. 19(5), 329-335 (2002).
127. Adams DM, Kinney TR, O'Branski-Rupp E, Ware RE. High-dose oral dexamethasone therapy for chronic childhood idiopathic thrombocytopenic purpura. J. Pediatr. 128(2), 281-283 (1996).
128. Kuhne T, Freedman J, Semple JW et al. Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura. J. Pediatr. 130(1), 17-24 (1997).
129. Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann. Hematol. 83(12), 764-768 (2004).
130. Caulier MT, Rose C, Roussel MT et al. Pulsed high-dose dexamethasone in refractory chronic idiopathic thrombocytopenic purpura: a report on 10 cases. Br. J. Haematol. 91(2), 477-479 (1995).
131. Bode C, Koerholz D, Janssen G, Schwamborn D, Goebel U. Poor response to pulsed high-dose dexamethasone therapy in children with resistant immune thrombocytopenic purpura. Eur. J. Pediatr. 155(10), 917 (1996).
132. Schiavotto C, Ruggeri M, Castaman G, Rodeghiero F. High-dose dexamethasone in adult refractory idiopathic thrombocytopenic purpura. Br. J. Haematol. 93(2), 491-492 (1996).
133. Borgna-Pignatti C, Rugolotto S, Nobili B et al. A trial of high-dose dexamethasone therapy for chronic idiopathic thrombocytopenic purpura in childhood. J. Pediatr. 130(1), 13-16 (1997).
134. Chen JS, Wu JM, Chen YJ, Yeh TF. Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. J. Pediatr. Hematol. Oncol. 19(6), 526-529 (1997).
135. Demiroglu H, Dundar S. High-dose pulsed dexamethasone for immune thrombocytopenia. N. Engl. J. Med. 337(6), 425-427 (1997).
136. Warner M, Wasi P, Couban S et al. Failure of pulse high-dose dexamethasone in chronic idiopathic immune thrombocytopenia. Am. J. Hematol. 54(4), 267-270 (1997).
137. Stasi R, Brunetti M, Pagano A et al. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol. Dis. 26(6), 582-586 (2000).
138. Cheng Y, Wong RS, Soo YO et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N. Engl. J. Med. 349(9), 831-836 (2003).
139. Mazzucconi MG, Fazi P, Bernasconi S et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 109(4), 1401-1407 (2007).
140. Banchereau J, Bazan F, Blanchard D et al. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12, 881-922 (1994).
141. Noelle RJ, Roy M, Shepherd DM et al. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl Acad. Sci. USA 89(14), 6550-6554 (1992).
142. Armitage RJ, Fanslow WC, Strockbine L et al. Molecular and biological characterization of a murine ligand for CD40. Nature 357(6373), 80-82 (1992).
143. Kato T, Kokuho T, Tamura T, Nariuchi H. Mechanisms of T cell contact-dependent B cell activation. J. Immunol. 152(5), 2130-2138 (1994).
144. Kuwana M, Kawakami Y, Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura. Blood 101(2), 621-623 (2003).
145. Nomura S, Kuwana M, Ikeda Y. Induction of T-cell tolerance in a patient with idiopathic thrombocytopenic purpura by single injection of humanized monoclonal antibody to CD40 ligand. Autoimmunity 36(5), 317-319 (2003).
146. Kuwana M, Nomura S, Fujimura K et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 103(4), 1229-1236 (2004).